U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07896213) titled 'Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia' on Oct. 19.
Brief Summary: The goal of this trial is to determine safe dosing of CD19-CD34t metabolically programmed CAR-T cell therapy in adult patients with CD19-positive B-cell acute lymphocytic leukemia (B-ALL).
The main questions it aims to answer are to determine the maximum tolerated dose (MTD) of CD19-CD34t metabolically programmed CAR-T cell therapy, to assess the safety of CD19-CD34t metabolically programmed CAR-T cell therapy, and to determine the feasibility of manufacturing CD19-CD34t metabolic...